Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder
life science investing Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
life science investing Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
life science investing Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
life science investing Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
Torchlight Innovations (Doing Business as RZOLV Technologies) Announces Preliminary Positive Results on Rare Earth and Critical Mineral Recoveries
